Curi Bio Analysis
What is Curi Bio?
Human iPSC-based 3D tissue models for cardiac, skeletal muscle, and disease modeling
Location
Seattle, United States
Employees
11-50
Founded
2015
Product Features & Capabilities
- Mantarray™ 3D tissue contractility analysis
- Mantarray Mini Plates for fewer cells, more data
- Nautilai™ voltage and calcium imaging
- Stingray™ tissue maturation
- NanoSurface™ plates for structural maturation
- Pulse™ high-throughput video contractility software
- Celo.Cardiomyocytes and skeletal muscle myoblasts
- Curi Engine™ services for compound profiling, assay development, and discovery
Use Cases
Screen compounds for cardiac toxicity using 3D engineered heart tissues; Test drug efficacy on Duchenne muscular dystrophy disease models; Evaluate muscle contractility in 2D and 3D skeletal muscle models; Perform high-throughput screening of drug candidates with Pulse™ software; Develop new assays using Curi Engine™ services; Assess calcium signaling in cardiac cells with Nautilai™; Validate drug potency in mature 3D muscle tissues
Other Considerations
Recognized as a 2024 Deloitte Technology Fast 500 winner; Named a 2021 Fast Company World Changing Ideas Award finalist; Selected as a 2021 AI & Data category finalist in Fast Company's World Changing Ideas Awards; Wins 2020 Xconomy Big Idea of the Year Award; Wins 2020 Tibbetts Award; Finalist for 2021 Edison Award
See something that needs updating? Suggest edits to this profile.